International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102

Strengthening the international scientific recognition of NFL Biosciences’ tobacco franchise within the leading scientific community dedicated to nicotine and tobacco research

Oral presentation dedicated to NFL-102, covering the regional effects of the drug candidate on neuroimmune and signaling pathways in a mouse model of tobacco-smoke exposure

Two scientific posters selected, respectively covering the IgG1 predictive biomarker associated with NFL-101 efficacy and the rationale and design of the TONIC clinical trial evaluating NFL-102

Regulatory News:

International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102

Related reading

NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized…

NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking…

Brainomix to Present Five New Studies at ERS Congress Demonstrating the…

Tract Bio Announces Presentations at Two AACR Conferences

Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in…

RESEARCH ADVANCES FROM THE 2026 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE